<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00331955</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02695</org_study_id>
    <secondary_id>MCC 14193</secondary_id>
    <secondary_id>CDR0000471997</secondary_id>
    <secondary_id>NCI-6970</secondary_id>
    <secondary_id>MCC-IRB-103476</secondary_id>
    <secondary_id>R21CA112913</secondary_id>
    <nct_id>NCT00331955</nct_id>
    <nct_alias>NCT00365079</nct_alias>
  </id_info>
  <brief_title>Vorinostat and Doxorubicin in Treating Patients With Metastatic or Locally Advanced Solid Tumors</brief_title>
  <official_title>Phase I Trial of Vorinostat (NSC-701852, Suberoylanilide Hydroxamic Acid) and Doxorubicin (NSC-123127, Adriamycin)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I trial is studying the side effects and best dose of vorinostat when given&#xD;
      together with doxorubicin in treating patients with metastatic or locally advanced solid&#xD;
      tumors. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed&#xD;
      for cell growth. Drugs used in chemotherapy, such as doxorubicin, work in different ways to&#xD;
      stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Vorinostat may help doxorubicin work better by making tumor cells more sensitive to&#xD;
      the drug.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the safety and tolerability of vorinostat (SAHA) and doxorubicin hydrochloride&#xD;
      in patients with metastatic or locally advanced solid tumors.&#xD;
&#xD;
      II. Determine the maximum tolerated dose of vorinostat when administered with doxorubicin&#xD;
      hydrochloride in patients treated with this regimen.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the response rate (complete response [CR] and partial response [PR]) and&#xD;
      clinical benefits rate (CR, PR, and stable disease &gt; 12 weeks) in patients treated with this&#xD;
      regimen.&#xD;
&#xD;
      II. Determine the pharmacokinetics and pharmacodynamics of vorinostat and doxorubicin&#xD;
      hydrochloride and their interaction.&#xD;
&#xD;
      III. Determine the effects of vorinostat on histone acetylation in peripheral blood&#xD;
      mononuclear cells and tumors.&#xD;
&#xD;
      IV. Determine the effects of vorinostat on DNA damage induced by doxorubicin hydrochloride as&#xD;
      a function of topoisomerase II expression.&#xD;
&#xD;
      V. Determine the effects of vorinostat on genes and proteins crucial for the maintenance of&#xD;
      chromatin structure.&#xD;
&#xD;
      OUTLINE: This is a non-randomized, open-label, dose-escalation study of vorinostat.&#xD;
&#xD;
      Patients receive oral vorinostat twice daily for 5 doses on days 1-3, 8-10, and 15-17 and&#xD;
      doxorubicin hydrochloride IV on days 3, 10, and 17. Treatment repeats every 28 days for up to&#xD;
      6 courses in the absence of disease progression or unacceptable toxicity. Patients with&#xD;
      responding or stable disease after 6 courses of treatment may continue to receive vorinostat&#xD;
      alone in the absence of disease progression.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of vorinostat until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity. Up to15 patients are treated at the MTD.&#xD;
      Mandatory biopsies are required in these patients. Patients undergo blood collection and&#xD;
      tumor biopsies periodically during the study for pharmacologic, pharmacokinetic,&#xD;
      pharmacodynamic, and biomarker correlative studies.&#xD;
&#xD;
      After completion of study treatment, patients are followed for at least 30 days.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 40 patients will be accrued to this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability as assessed by NCI CTCAE v3.0</measure>
    <time_frame>Up to 30 days after completion of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of vorinostat as assessed by NCI CTCAE v3.0</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effects of vorinostat on histone acetylation</measure>
    <time_frame>At baseline and at day 3 prior</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of dose and response with biological markers for histone acetylation, Topo II expression, assays for comet moments and expression patterns of chromatin structural proteins dose</measure>
    <time_frame>Up to 30 days after completion of study treatment</time_frame>
    <description>Our initial analysis of efficacy will be descriptive and exploratory with the goal of discerning trends in various response endpoints and correlation with biological markers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate (CR and PR) and clinical benefits rate (CR, PR, and stable disease) according to RECIST</measure>
    <time_frame>Up to 30 days after completion of study treatment</time_frame>
    <description>Our initial analysis of efficacy will be descriptive and exploratory with the goal of discerning trends in various response endpoints and correlation with biological markers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (overall response, complete response, and stable disease)</measure>
    <time_frame>Up to 30 days after completion of study treatment</time_frame>
    <description>Using Cox regression with dose as an independent variable.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Treatment (vorinostat, doxorubicin hydrochloride)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral vorinostat twice daily for 5 doses on days 1-3, 8-10, and 15-17 and doxorubicin hydrochloride IV on days 3, 10, and 17. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with responding or stable disease after 6 courses of treatment may continue to receive vorinostat alone in the absence of disease progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (vorinostat, doxorubicin hydrochloride)</arm_group_label>
    <other_name>ADM</other_name>
    <other_name>ADR</other_name>
    <other_name>Adria</other_name>
    <other_name>Adriamycin PFS</other_name>
    <other_name>Adriamycin RDF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vorinostat</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Treatment (vorinostat, doxorubicin hydrochloride)</arm_group_label>
    <other_name>L-001079038</other_name>
    <other_name>SAHA</other_name>
    <other_name>suberoylanilide hydroxamic acid</other_name>
    <other_name>Zolinza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (vorinostat, doxorubicin hydrochloride)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (vorinostat, doxorubicin hydrochloride)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed solid tumor malignancies for which no&#xD;
             curative therapy exists&#xD;
&#xD;
          -  Measurable or evaluable disease with tumor that is accessible to biopsy as determined&#xD;
             by CT scan or ultrasound&#xD;
&#xD;
          -  Skin, lymph nodes, or chest wall lesions are allowed provided measurements are&#xD;
             confirmed by 2 independent health care professionals&#xD;
&#xD;
          -  No uncontrolled CNS metastases&#xD;
&#xD;
               -  Patients with stable CNS metastases (either surgically resected, treated with&#xD;
                  gamma knife, or stable for 3 months after whole-brain radiotherapy and documented&#xD;
                  by MRI within the past 4 weeks) are eligible&#xD;
&#xD;
          -  Willing to undergo pre- and post-vorinostat tumor biopsies&#xD;
&#xD;
          -  Life expectancy ≥ 3 months&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  WBC &gt; 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,500/mm^3&#xD;
&#xD;
          -  Hemoglobin &gt; 9.0 g/dL&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm^3 (transfusion independent)&#xD;
&#xD;
          -  Creatinine ≤ 2.0 mg/mL&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT ≤ 1.5 times ULN&#xD;
&#xD;
          -  LVEF &gt; 50%&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 6 months after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  No significant active infection (e.g., pneumonia, cellulitis, or wound abscess)&#xD;
&#xD;
          -  No history of cardiac failure&#xD;
&#xD;
          -  No history of long QT syndrome (QTc &gt; 470 msec)&#xD;
&#xD;
          -  No history of ventricular tachycardia or fibrillation&#xD;
&#xD;
          -  No history of seizures&#xD;
&#xD;
          -  No history of allergic reactions attributed to compounds of similar chemical or&#xD;
             biological composition to vorinostat or other agents used in the study&#xD;
&#xD;
          -  More than 3 weeks since prior chemotherapy or radiotherapy (2 weeks for weekly&#xD;
             regimens)&#xD;
&#xD;
          -  More than 2 weeks since prior valproic acid or any other histone deacetylase&#xD;
             inhibitors&#xD;
&#xD;
          -  No prior anthracycline exposure&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
          -  No concurrent hormonal therapy except for maintenance therapy with luteinizing-hormone&#xD;
             releasing-hormone agonists&#xD;
&#xD;
          -  No concurrent antiarrhythmics&#xD;
&#xD;
          -  No concurrent steroids to control brain metastasis&#xD;
&#xD;
          -  No concurrent colony-stimulating factors (e.g., filgrastim [G-CSF] or sargramostim&#xD;
             [GM-CSF]) during the first course of study treatment&#xD;
&#xD;
          -  No other concurrent investigational agents for primary disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Wenham</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>May 30, 2006</study_first_submitted>
  <study_first_submitted_qc>May 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2006</study_first_posted>
  <last_update_submitted>July 1, 2013</last_update_submitted>
  <last_update_submitted_qc>July 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Vorinostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

